Mount Sinai Health System on Friday announced an exclusive multiyear license and partnership with RenalytixAI, an artificial-intelligence startup with offices in New York and the United Kingdom. The goal is to reduce the $98 billion in preventable kidney disease and dialysis costs by predicting which patients are at the greatest risk of advanced kidney disease and taking steps to treat them early on. The venture will draw from the more than 3 million electronic health records in Mount Sinai's system, plus an additional 43,000 patient records in Mount Sinai's BioMe BioBank, part of the Charles Bronfman Institute for Personalized Medicine. The bank collects DNA and blood serum from a diverse patient base to identify biomarkers, substances that can indicate disease, infection or environmental exposure. All data will be de-identified to protect patient privacy "We can look at relationships that we could never look at before," said RenalytixAI CEO James McCullough.